PHARMACY

Crescita's Pliaglis received approval from the Food and Drug Administration for removal of the "Not for Home Use" label restriction.

LexisNexis Risk Solutions' Craig Ford looks at how pharmacists play a key role in care delivery as patients can walk right up to the counter with a question without an appointment.

Hy-Vee's pharmacies are aiming to combat the opioid epidemic with a new controlled substance prescription policy.

Braeburn's Brixadi offers treatment for patients with moderate-to-severe opioid use disorder.

The FDA has approved Alembic's generic Mirapex and Patanol, which had a market value of roughly $38.6 million, and $61 million, respectively.

Sanofi and Merck received the FDA's approval for a new vaccine that will not have a commerical supply available in the United States prior to 2020.

Lupin and AbbVie have formed a partnership to develop Lupin's MALT1 inhibitors.

Hikma expects its deal with Sciecure will expand its pipeline of niche products.